Difference between revisions 796940716 and 801192002 on enwiki

{{Orphan|date=August 2017}}

{{Infobox company
| name = Frequency Therapeutics
| logo = 
| type = 
| industry = [[Biotechnology]]
| fate = 
(contracted; show full)so|url=https://www.bostonglobe.com/business/2017/04/11/new-woburn-biotech-targets-hearing-loss-with-mit-partners-discoveries/LEmIDgqmYm8KimC4FfBdsM/story.html|work=[[Boston Globe]]|location= |access-date= }}</ref><ref>{{cite news |last= |first= |date= |title=Farmington Medical Startup Targets Hearing Loss With New Drugs|url=http://www.courant.com/business/hc-hearing-loss-startuprecovered-fri-may--5-084003-2017--20170505-story.html|work=[[Hartford Courant]]|location= |access-date= }}</ref>
This organization was co-founded by MIT professor [[Bob Langer]], who is known for his work in the areas of controlled [[drug delivery]] and [[tissue engineering]]<ref name=":0">{{Cite web|url=https://www.bizjournals.com/boston/news/2017/04/11/hearing-loss-biotech-frequency-therapeutics-dials.html|title=https://www.bizjournals.com/boston/news/2017/04/11/hearing-loss-biotech-frequency-therapeutics-dials.html|website=www.bizjournals.com|access-date=2017-09-18}}</ref>, Harvard Medical School professor Jeff Karp and David Lucchino.

The company is developing drugs aimed at regenerating [[cochlea]]r cells, whose damage is often cause of hearing loss.<ref>{{cite journal |last1=Sheridan|first1=Cormac|title=Interest rekindles in drug cocktails that reprogram cells|url=https://www.nature.com/nbt/journal/v35/n6/full/nbt0617-489.html|journal=[[Nature (journal)|Nature]]|volume= |issue= |pages= |doi= |access-date=16 June 2017}}</ref> The company and its researchers have identified inhibitors of [[GSK3B]] and [[Histone deacetylase|HDAC]] as successfully promoting the generation of cochlear cells in vitro.<ref>{{cite journal |last1=McLean|first1=Will|title=Clonal Expansion of Lgr5-Positive Cells from Mammalian Cochlea and High-Purity Generation of Sensory Hair Cells|url=http://www.cell.com/cell-reports/pdf/S2211-1247(17)30136-5.pdf|journal=[[Cell (journal)|Cell]]|volume= |issue=|pages= |doi=10.1016/j.celrep.2017.01.066|access-date=16 June 2017}}</ref><ref>{{cite web |title=Frequency Therapeutics Announces a Revolutionary Small-molecule Approach to Restore Hearing Published in Cell Reports|last= |first= |date= |url=http://www.frequencytx.com/news-events/pr-02-21-2017.php|publisher=Frequency Therapeutics|access-date=16 June 2017|quote=}}</ref>

In 2017, the company raised $32 million in [[series A round]] funding led by CoBro Ventures, Mark Cohen, Emigrant Capital, Alexandria Real Estate Equities and Morningside Ventures. <ref name=":0" />⏎
⏎
==See also==
*[[Histone deacetylase inhibitor]]

==References==
{{reflist}}

==External links==
*[http://www.frequencytx.com/ Company website]

[[Category:Companies based in Massachusetts]]
[[Category:Companies established in 2015]]


{{biotech-stub}}